Sort   by:  
 Page size 
TranscriptomicsBortezomib resistance in THP-1 cell line
Bortezomib is a proteasome inhibitor used in severel different hematological malignancies. Resistance to this drug is still poorly understood. In order get more insight in the resistance mechanism, we developed several bortezomib resistant subclones of the THP-1 monocytic/macrophage cell line. On th...
ORGANISM(S): Homo sapiens 
2008-06-14 | E-GEOD-11771 | biostudies-arrayexpress
TranscriptomicsGenome-wide analysis of gene expression in response to bortezomib treatment [mouse cell lines II]
Genome-wide analysis of gene expression in response to bortezomib treatment(33 nM) in cell lines before and after selection for resistance. Multiple myeloma (MM) is a hematologic malignancy characterized by the proliferation of neoplastic plasma cells in the bone marrow. While the first-to-market pr...
ORGANISM(S): Mus musculus 
2013-07-02 | E-GEOD-41928 | biostudies-arrayexpress
TranscriptomicsGenome-wide analysis of gene expression in response to bortezomib treatment [mouse cell lines I]
Genome-wide analysis of gene expression in response to bortezomib treatment (33 nM) in cell lines before and after selection for resistance. Multiple myeloma (MM) is a hematologic malignancy characterized by the proliferation of neoplastic plasma cells in the bone marrow. While the first-to-market p...
ORGANISM(S): Mus musculus 
2013-07-02 | E-GEOD-41927 | biostudies-arrayexpress
TranscriptomicsGenome-wide analysis of gene expression in response to bortezomib treatment [human cell lines].
Genome-wide analysis of gene expression in response to bortezomib treatment (33 nM) in cell lines before and after selection for resistance. Multiple myeloma (MM) is a hematologic malignancy characterized by the proliferation of neoplastic plasma cells in the bone marrow. While the first-to-market p...
ORGANISM(S): Homo sapiens 
2013-07-02 | E-GEOD-41929 | biostudies-arrayexpress
TranscriptomicsBortezomib resistance in CCRF-CEM cell line [GEP]
Bortezomib is a proteasome inhibitor used in severel different hematological malignancies. Resistance to this drug is still poorly understood. In order get more insight in the resistance mechanism, we developed several bortezomib resistant subclones of the CCRF-CEM T-ALL cell line. On these subclone...
ORGANISM(S): Homo sapiens 
2015-11-04 | E-GEOD-74634 | biostudies-arrayexpress
TranscriptomicsBortezomib inhibits mTOR pathway in multiple myeloma cells via induced expression of REDD1.
The combination of bortezomib and dexamethasone should become the reference induction treatment for multiple myeloma patients younger than 65 years. Pharmacogenomic profiles of genes involved in response to treatment may help to understand resistance. We performed gene expression profiling in 9 myel...
ORGANISM(S): Homo sapiens 
2010-02-14 | E-GEOD-11866 | biostudies-arrayexpress
TranscriptomicsTranscription profiling of human samples from multiple myeloma patients treated with bortezomib or dexamethasone
The aims of this study were to assess the feasibility of prospective pharmacogenomics research in multicenter international clinical trials of bortezomib in multiple myeloma and to develop predictive classifiers of response and survival with bortezomib. Patients with relapsed myeloma enrolled in pha...
ORGANISM(S): Homo sapiens 
2008-06-17 | E-GEOD-9782 | biostudies-arrayexpress
ProteomicsProteomics-based approach reveals the involvement of SERPINB9 in recurrent and relapsed multiple myeloma
Multiple myeloma (MM) is a common hematological malignancy with poorly understood recurrence and relapse mechanisms. Notably, bortezomib resistance leading to relapse makes MM treatment significantly challenging. To clarify the drug resistance mechanism, we employed a quantitative proteomics approac...
ORGANISM(S): Homo sapiens (Human) 
2021-03-03 | PXD022182 | Pride
Multiple myeloma  recurrence and relapse  proteomics  parallel reaction monitoring  serpinb9 
TranscriptomicsEffect of treatment OPM2 multiple myeloma cells with EPA, DHA or bortezomib
OPM2 cells were seeded in a 12-well plate at density of 10 × 103 cells/well and incubated with the indicated concentrations of compounds. OPM2 cells were treated with 50 µM of DHA/EPA (6 h) or 10 nM of bortezomib (4 h). Total RNA was extracted from cells using RNeasy Mini Kit (74104, Qiagen, Hilden,...
ORGANISM(S): Homo sapiens 
2022-06-26 | E-MTAB-11907 | biostudies-arrayexpress
TranscriptomicsMolecular Mechanisms of Bortezomib Resistant Adenocarcinoma cells [GEP data]
Copy number and Gene expression profiling of HT-29 wild-type and bortezomib resistant cell lines Identification of mechanisms of bortezomib resistance Gene expression differences between HT-29 cell line variants
ORGANISM(S): Homo sapiens 
2011-06-04 | E-GEOD-29712 | biostudies-arrayexpress
Sort   by:  
 Page size